Stoke Therapeutics (STOK) Interest & Investment Income (2019 - 2026)
Stoke Therapeutics' quarterly Interest & Investment Income came in at $3.4 million in Q1 2026, up 18.34% year-on-year from $2.9 million in Q1 2025, and down 5.39% quarter-over-quarter from $3.6 million in Q4 2025.
Stoke Therapeutics has reported Interest & Investment Income for 8 years, with the latest figure at $3.4 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 18.34% year-over-year to $3.4 million; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (up 9.06% YoY), and the FY2025 full-year result was $13.8 million, up 8.85% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $3.4 million, down from $3.6 million in the prior quarter.
- The five-year high for Interest & Investment Income was $3.8 million in Q2 2025, with the low at $104000.0 in Q1 2022.
- Average Interest & Investment Income over 5 years is $2.5 million, with a median of $2.7 million recorded in 2023.
- Year-over-year, Interest & Investment Income jumped 4008.33% in 2022 and fell 2.31% in 2025.
- Tracing STOK's Interest & Investment Income over 5 years: stood at $1.5 million in 2022, then soared by 74.92% to $2.6 million in 2023, then increased by 14.8% to $3.0 million in 2024, then advanced by 21.72% to $3.6 million in 2025, then fell by 5.39% to $3.4 million in 2026.
- The last three Interest & Investment Income figures came in at $3.4 million (Q1 2026), $3.6 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 3.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.42 Mn |
| Dec 31, 2025 | 3.62 Mn |
| Sep 30, 2025 | 3.46 Mn |
| Jun 30, 2025 | 3.79 Mn |
| Mar 31, 2025 | 2.89 Mn |
| Dec 31, 2024 | 2.97 Mn |
| Sep 30, 2024 | 3.55 Mn |
| Jun 30, 2024 | 3.70 Mn |
| Mar 31, 2024 | 2.43 Mn |
| Dec 31, 2023 | 2.59 Mn |
| Sep 30, 2023 | 2.65 Mn |
| Jun 30, 2023 | 2.57 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 1.48 Mn |
| Sep 30, 2022 | 995,000.00 |
| Jun 30, 2022 | 544,000.00 |
| Mar 31, 2022 | 104,000.00 |
| Dec 31, 2021 | 36,000.00 |
| Sep 30, 2021 | 44,000.00 |
| Jun 30, 2021 | 34,000.00 |
| Mar 31, 2021 | 6,000.00 |
| Dec 31, 2020 | -3,000.00 |
| Sep 30, 2020 | -1,000.00 |
| Jun 30, 2020 | 39,000.00 |
| Mar 31, 2020 | 674,000.00 |
| Dec 31, 2019 | 904,000.00 |
| Sep 30, 2019 | 1.24 Mn |
| Jun 30, 2019 | 629,000.00 |
| Mar 31, 2019 | 580,000.00 |